PMGC unit NorthStrive Biosciences launches independent FACS study for EL-22 manufacturing comparability
PUBT · 1d ago
Share
Listen to the news
- NorthStrive Biosciences, a PMGC Holdings unit, plans an independent flow cytometry (FACS) study to quantify EL-22 latent myostatin antigen expression.
- Program targets manufacturing comparability between NorthStrive-produced engineered Lactobacillus casei and prior EL-22 material made by MOA Life Plus.
- Work aims to strengthen EL-22 product identity and manufacturing consistency, supporting IND-enabling development for the engineered probiotic candidate.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607100730PRIMZONEFULLFEED9760166) on July 10, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved